The Horizons ETFs Makes Q1 Update

The main exchange for listing psychedelics companies, Horizons Psychedelic Stock Index ETF, has completed its first quarterly rebalance of its holdings. Horizons ETFs has over US$17.5 billion of assets under management and 88 ETFs ...

Australia to Provide $15m to Support Research into Psychedelic Medicines

Last week, the Australian government announced it would provide $15m of funding to support research into psychedelic medicines and their impact on treating mental health conditions. The Mental Illness Grant Opportunity represents a new ...

First ketamine-assisted psychotherapy clinic opens in the UK

Laurie Higbed, Ben Sessa and Steve O’Brien: Awakn Life Sciences | Photograph: Joel Redman/The Guardian Awakn Life Sciences has opened a clinic offering ketamine-assisted psychotherapy in the UK, becoming the first of its kind in the ...

Results of Global Drug Survey Published

Recently published results of The Global Drug Survey have revealed the behaviour and experiences of people using the likes of psilocybin, LSD, DMT MDMA and other psychedelics to aid their wellbeing and mental health. The online study ...

Results of Major Study on Impact of Microdosing Published

Researchers from Imperial College London have carried out the largest placebo-controlled trial into psychedelics to date and found that small doses of LSD boost the psychology of users in a manner of ways. However, when the researchers ...

An Analysis of Microdosing Psychedelics

During The PSYCH Symposium in November 2020, a panel of leading scientists discussed their work in the field of psychedelic medicines as well as the research they had conducted on microdosing and the impact it has on the human body. ...

When Mother Nature Becomes Big Business

During The PSYCH Symposium in November 2020, a panel of leading experts operating in psychedelics sector, discussed the cultural challenge of commercialising the likes of psilocybin, DMT and LSD. This discussion, featuring a number of ...

Psychedelics Industry Achieves Investment Milestone

Last week, the world’s first exchange-traded fund for psychedelic medicines companies made its debut in Toronto, as the investment sector aims to capitalise on the rapidly developing interest in prospective mental health ...

Project Psilocybin and the Future of the Psychedelics Industry

During The PSYCH Symposium in November 2020, a panel of leading experts,operating in psychedelics sector discussed the advancement of research on psilocybin. The groundbreaking, rapid progress being made in a number of regions across ...

Professor David Nutt: The Therapeutic Use of Psychedelics

During The PSYCH Symposium in November 2020, Professor David Nutt, chairman of Awakn Life Sciences, founder of Drug Science and the director of neuropsychopharmacology at Imperial College London, delivered a virtual keynote speech on ...